India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

Zydus Lifesciences Ltd share price was down by -3.65% from the previous closing price of ₹957.60. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...

India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK) ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary. CVS ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Nippon India Small Cap Fund - Direct (G) 560.96 28,45,731 0.91 Nippon India Small Cap Fund - Direct (B) 560.96 28,45,731 0.91 Nippon India Small Cap Fund (B) 560.96 ...

Share price of Zydus Lifesciences fell as much as 0.77% to Rs 1,002.75 apiece, the lowest level since Jan. 8, 2025. It pared loss to trade 0.07% higher at Rs 1,011.25 apiece, as of 9:33 a.m. This ...

ICICI Pru Regular Savings Fund (G) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-M) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-Q) 6.13 62,263 0.19 ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the 25th anniversary of its Vashi plant. The facility is crucial for ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.